In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 2.82 below Can Fite Biopharma Ltd average.

Within Major Pharmaceutical Preparations industry 193 other companies have achieved higher Quick Ratio than Can Fite Biopharma Ltd in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 711 to 734.

Explain Quick Ratio?
How much Cash & cash equivalents CANF�s has?
What are CANF�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CANF Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	28.73 %	33.09 %	-11 %	33.09 %	97.07 %
Y / Y Cash & cash equivalent Change	8.28 %	8.28 %	-17.07 %	8.28 %	-11.6 %
Quick Ratio MRQ	2.82	3.13	3.03	3.13	3.35
CANF's Total Ranking	# 734	# 711	#	#	#
Seq. Current Liabilities Change	10.91 %	28.34 %	-22.08 %	16.06 %	14.67 %
Seq. Cash & cash equivalent Change	0 %	32.28 %	-24.4 %	8.28 %	0 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 194
Healthcare Sector	# 341
Overall Market	# 734

Quick Ratio Statistics
High	Average	Low
7.15	3.72	0.82
(Dec 31 2021)		(Dec 31 2019)

Financial Statements
Can Fite Biopharma Ltd 's Current Liabilities	$ 3 Millions	Visit CANF's Balance sheet
Can Fite Biopharma Ltd 's Cash & cash equivalent	$ 9 Millions	Visit CANF's Balance sheet
Source of CANF's Sales		Visit CANF's Sales by Geography

Cumulative Can Fite Biopharma Ltd 's Quick Ratio

CANF's Quick Ratio for the trailling 12 Months

CANF Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	20.02 %	29.31 %	18.37 %	13.03 %	-0.35 %
Y / Y Cash & cash equivalent TTM Growth	2 %	-3.26 %	-10.03 %	-6.69 %	-8.85 %
Quick Ratio TTM	3.02	3.16	3.32	3.37	3.55
Total Ranking TTM	# 2573	# 3475	#	#	#
Seq. Current Liabilities TTM Growth	6.8 %	7.33 %	-2.76 %	7.67 %	15.07 %
Seq. Cash & cash equivalent TTM Growth	2.08 %	2.12 %	-4.14 %	2.08 %	-3.19 %

Quick ratio ranking by company, industry and sector >> Back to CANF Financial Strength Comparisons >> Go to Compare CANF Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q4 2025 to $3.03 millions, cumulative Quick Ratio decreased to 3.02 below the Can Fite Biopharma Ltd average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 322 other companies have achieved higher Quick Ratio than Can Fite Biopharma Ltd . While Quick Ratio overall ranking has improved so far to 2573, from total ranking during the twelve months ending third quarter 2025 at 3475.

Explain Quick Ratio?
How much Cash & cash equivalents CANF�s has?
What are CANF�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 323
Healthcare Sector	# 680
Within the Market	# 2573

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.01	3.88	0.82
(Dec 31 2021)		(Dec 31 2019)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Atea Pharmaceuticals Inc	7.75	$ 301.830 Millions	$ 38.941 Millions
Anixa Biosciences Inc	7.71	$ 15.174 Millions	$ 1.967 Millions
Shattuck Labs Inc	7.68	$ 54.192 Millions	$ 7.052 Millions
Scynexis Inc	7.62	$ 40.031 Millions	$ 5.251 Millions
Avalo Therapeutics Inc	7.60	$ 98.373 Millions	$ 12.940 Millions
Milestone Pharmaceuticals Inc	7.58	$ 105.960 Millions	$ 13.979 Millions
Acrivon Therapeutics Inc	7.57	$ 118.582 Millions	$ 15.664 Millions
Annovis Bio Inc	7.54	$ 19.532 Millions	$ 2.591 Millions
Newamsterdam Pharma Company N v	7.40	$ 636.241 Millions	$ 86.036 Millions
Adicet Bio Inc	7.36	$ 158.530 Millions	$ 21.531 Millions
Novabridge Biosciences	7.33	$ 210.842 Millions	$ 28.781 Millions
Day One Biopharmaceuticals Inc	7.29	$ 441.113 Millions	$ 60.522 Millions
Eledon Pharmaceuticals Inc	7.27	$ 133.336 Millions	$ 18.344 Millions
Marker Therapeutics inc	7.07	$ 16.068 Millions	$ 2.274 Millions
Camp4 Therapeutics Corporation	7.06	$ 109.517 Millions	$ 15.514 Millions
Barinthus Biotherapeutics Plc	7.03	$ 70.456 Millions	$ 10.018 Millions
Xenon Pharmaceuticals Inc	7.02	$ 548.886 Millions	$ 78.167 Millions
Stablecoin Development Corporation	6.97	$ 7.958 Millions	$ 1.142 Millions
Centessa Pharmaceuticals Plc	6.86	$ 294.580 Millions	$ 42.935 Millions
Tonix Pharmaceuticals Holding Corp	6.73	$ 207.637 Millions	$ 30.837 Millions
Zentalis Pharmaceuticals Inc	6.73	$ 245.893 Millions	$ 36.559 Millions
An2 Therapeutics Inc	6.65	$ 58.001 Millions	$ 8.720 Millions
Actinium Pharmaceuticals Inc	6.62	$ 47.998 Millions	$ 7.247 Millions
Gain Therapeutics inc	6.45	$ 20.838 Millions	$ 3.233 Millions
Nuvation Bio Inc	6.44	$ 529.211 Millions	$ 82.231 Millions
Vistagen Therapeutics Inc	6.38	$ 80.482 Millions	$ 12.612 Millions
Arcturus Therapeutics Holdings Inc	6.35	$ 230.909 Millions	$ 36.379 Millions
Wave Life Sciences Ltd	6.33	$ 602.068 Millions	$ 95.065 Millions
Korro Bio Inc	6.30	$ 75.156 Millions	$ 11.937 Millions
Rocket Pharmaceuticals Inc	6.25	$ 188.929 Millions	$ 30.206 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.